Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease.
ELLIPTA
critical errors
inhaled corticosteroid
inhaler technique
long-acting muscarinic antagonist
long-acting β2-agonist
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
07
2019
accepted:
21
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
29
6
2021
Statut:
epublish
Résumé
Training in correct inhaler use, ideally in person or by video demonstration, can minimize errors but is rarely provided in clinics. This open-label, low-intervention study evaluated critical error rates with dry-powder inhalers (DPIs), before and after training, in patients with chronic obstructive pulmonary disease. Patients prescribed an inhaled corticosteroid (ICS)/long-acting β The intent-to-treat population comprised 450 patients. At V1, fewer patients made ≥1 critical error with ELLIPTA (10%) versus other ICS/LABA DPIs (Turbuhaler: 40%, OR 4.66, Fewer patients made critical errors with ELLIPTA versus other ICS/LABA, and LAMA or LAMA/LABA DPIs. The effect of "verbal" training highlights its importance for reducing critical errors with common DPIs.
Identifiants
pubmed: 32606640
doi: 10.2147/COPD.S224209
pii: 224209
pmc: PMC7294437
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Muscarinic Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1301-1313Informations de copyright
© 2020 Collier et al.
Déclaration de conflit d'intérêts
David J Collier was supported in part by the NIHR Barts Biomedical Research Centre. Job van der Palen reports personal fees from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline plc., and grants from Chiesi, outside the submitted work. Logan Heyes was an employee of GlaxoSmithKline plc. at the time of the study, and is currently employed by Pharmaceutical Management Agency (PHARMAC). Dawn Midwinter, Kathryn Collison, Andy Preece, Neil Barnes, and Raj Sharma are employees of, and have shares in, GlaxoSmithKline plc. The authors report no other conflicts of interest in this work.
Références
Ther Clin Risk Manag. 2019 Mar 14;15:461-472
pubmed: 30936708
J Aerosol Med. 2003 Fall;16(3):249-54
pubmed: 14572322
Respir Med. 2011 Jun;105(6):930-8
pubmed: 21367593
Respir Med. 2013 Jan;107(1):37-46
pubmed: 23098685
Int J Chron Obstruct Pulmon Dis. 2018 Jun 15;13:1949-1963
pubmed: 29942127
J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):247-255
pubmed: 28277810
NPJ Prim Care Respir Med. 2016 Nov 24;26:16079
pubmed: 27883002
J Asthma. 2007 Oct;44(8):593-8
pubmed: 17943567
NPJ Prim Care Respir Med. 2017 Apr 3;27(1):22
pubmed: 28373682
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1071-1081.e9
pubmed: 28286157
Respir Res. 2018 Jan 16;19(1):10
pubmed: 29338792
J Asthma. 2011 Aug;48(6):616-24
pubmed: 21623690
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):987-995
pubmed: 29355645
NPJ Prim Care Respir Med. 2017 Apr 13;27(1):24
pubmed: 28408742
Int J Chron Obstruct Pulmon Dis. 2014 Dec 11;9:1365-75
pubmed: 25525354
Respir Med. 2008 Apr;102(4):593-604
pubmed: 18083019
Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2515-2523
pubmed: 30174421
Eur Respir J. 2017 Feb 15;49(2):
pubmed: 28182569
NPJ Prim Care Respir Med. 2015 Apr 30;25:15018
pubmed: 25927321